NE

Nectar Lifesciences LtdNSE NECLIFE Stock Report

Last reporting period 31 Mar, 2024

Updated 07 Nov, 2024

Last price

Market cap $B

0.035

Micro

Exchange

XNSE - National Stock Exchange Of India

NECLIFE.NS Stock Analysis

NE

Uncovered

Nectar Lifesciences Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

28/100

Low score

Market cap $B

0.035

Dividend yield

0.49 %

Shares outstanding

224.26 B

Nectar Lifesciences Ltd. is a holding company, which engages in the manufacture and distribution of pharmaceutical products. The company is headquartered in Chandigarh, Chandigarh and currently employs 1,589 full-time employees. The company went IPO on 2005-07-19. The firm's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The firm is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The firm offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.

View Section: Eyestock Rating